These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 7722117

  • 1. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.
    Hallstrom A, Pratt CM, Greene HL, Huther M, Gottlieb S, DeMaria A, Young JB.
    J Am Coll Cardiol; 1995 May; 25(6):1250-7. PubMed ID: 7722117
    [Abstract] [Full Text] [Related]

  • 2. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) InvestigatorsThe CAPS Coordinating Center, University of Washington, JD-22, 1107 Northeast 45th, Room 505, Seattle, Washington 98105, USA..
    Am J Cardiol; 1988 Mar 01; 61(8):501-9. PubMed ID: 2894169
    [Abstract] [Full Text] [Related]

  • 3. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
    Anderson JL, Platia EV, Hallstrom A, Henthorn RW, Buckingham TA, Carlson MD, Carson PE.
    Circulation; 1994 Dec 01; 90(6):2843-52. PubMed ID: 7994829
    [Abstract] [Full Text] [Related]

  • 4. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
    Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K, Morganroth J, Schlant RC, Waldo AL.
    J Am Coll Cardiol; 1991 Nov 15; 18(6):1434-8. PubMed ID: 1939943
    [Abstract] [Full Text] [Related]

  • 5. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
    Akiyama T, Pawitan Y, Campbell WB, Papa L, Barker AH, Rubbert P, Friedman L, Keller M, Josephson RA.
    J Am Geriatr Soc; 1992 Jul 15; 40(7):666-72. PubMed ID: 1607582
    [Abstract] [Full Text] [Related]

  • 6. Late ventricular potentials in risk assessment of the occurrence of complex ventricular arrhythmia in patients with myocardial infarction and heart failure.
    Cosić Z, Tavcioski D, Jovelić A, Romanović R.
    Vojnosanit Pregl; 2004 Jul 15; 61(6):589-97. PubMed ID: 15717719
    [Abstract] [Full Text] [Related]

  • 7. Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
    Hallstrom AP, Anderson JL, Carlson M, Davies R, Greene HL, Kammerling JM, Romhilt DW, Duff HJ, Huther M.
    Am Heart J; 1995 Jul 15; 130(1):71-9. PubMed ID: 7611126
    [Abstract] [Full Text] [Related]

  • 8. Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
    Am J Cardiol; 1988 Apr 01; 61(10):704-13. PubMed ID: 2451414
    [Abstract] [Full Text] [Related]

  • 9. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
    Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL.
    N Engl J Med; 1991 Mar 21; 324(12):781-8. PubMed ID: 1900101
    [Abstract] [Full Text] [Related]

  • 10. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. The Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators.
    el-Sherif N, Denes P, Katz R, Capone R, Mitchell LB, Carlson M, Reynolds-Haertle R.
    J Am Coll Cardiol; 1995 Mar 15; 25(4):908-14. PubMed ID: 7884096
    [Abstract] [Full Text] [Related]

  • 11. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
    Epstein AE, Hallstrom AP, Rogers WJ, Liebson PR, Seals AA, Anderson JL, Cohen JD, Capone RJ, Wyse DG.
    JAMA; 1993 Nov 24; 270(20):2451-5. PubMed ID: 8230622
    [Abstract] [Full Text] [Related]

  • 12. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
    Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA.
    Am J Cardiol; 1991 Dec 15; 68(17):1551-5. PubMed ID: 1720917
    [Abstract] [Full Text] [Related]

  • 13. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
    Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW.
    J Am Coll Cardiol; 1992 Apr 15; 19(5):894-8. PubMed ID: 1552108
    [Abstract] [Full Text] [Related]

  • 14. Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction.
    Ersbøll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, Møller JE, Kisslo J, Velazquez EJ, Hassager C, Søgaard P, Køber L.
    JACC Cardiovasc Imaging; 2013 Aug 15; 6(8):851-60. PubMed ID: 23850252
    [Abstract] [Full Text] [Related]

  • 15. Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
    Anderson JL, Hallstrom AP, Griffith LS, Ledingham RB, Reiffel JA, Yusuf S, Barker AH, Fowles RE, Young JB.
    Circulation; 1989 Mar 15; 79(3):610-9. PubMed ID: 2465099
    [Abstract] [Full Text] [Related]

  • 16. Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1).
    Gorkin L, Schron EB, Brooks MM, Wiklund I, Kellen J, Verter J, Schoenberger JA, Pawitan Y, Morris M, Shumaker S.
    Am J Cardiol; 1993 Feb 01; 71(4):263-7. PubMed ID: 8427165
    [Abstract] [Full Text] [Related]

  • 17. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators.
    La Rovere MT, Bigger JT, Marcus FI, Mortara A, Schwartz PJ.
    Lancet; 1998 Feb 14; 351(9101):478-84. PubMed ID: 9482439
    [Abstract] [Full Text] [Related]

  • 18. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study.
    Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M.
    J Am Coll Cardiol; 1996 Feb 14; 27(2):270-6. PubMed ID: 8557893
    [Abstract] [Full Text] [Related]

  • 19. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
    Bigger JT, Rolnitzky LM, Steinman RC, Fleiss JL.
    J Am Coll Cardiol; 1994 Mar 01; 23(3):733-40. PubMed ID: 7509355
    [Abstract] [Full Text] [Related]

  • 20. Distinction between arrhythmic and nonarrhythmic death after acute myocardial infarction based on heart rate variability, signal-averaged electrocardiogram, ventricular arrhythmias and left ventricular ejection fraction.
    Hartikainen JE, Malik M, Staunton A, Poloniecki J, Camm AJ.
    J Am Coll Cardiol; 1996 Aug 01; 28(2):296-304. PubMed ID: 8800101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.